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Abstract The calcium and phosphate homeostasis is reg-
ulated by a complex interplay between parathyroid hor-
mone (PTH), fibroblast growth factor 23 (FGF23), and
calcitriol. Experimental studies have demonstrated an
inhibitory effect of FG23 on PTH production and secretion;
the physiological role of this regulation is however not well
understood. Surprisingly, in uremia, concomitantly ele-
vated FGF23 and PTH levels are observed. The parathyroid
gland rapidly loses its responsiveness to extracellular cal-
cium in vitro and a functional parathyroid cell line has
currently not been established. Therefore, the aim of the
present investigation was to study the impact of FGF23 on
the Ca2?/PTH relationship in vivo under conditions of
normocalcemia and hypocalcemia. Wistar rats were allo-
cated to treatment with intravenous recombinant FGF23
and inhibition of the FGF receptor in the setting of nor-
mocalcemia and acute hypocalcemia. We demonstrated
that FGF23 rapidly inhibited PTH secretion and that this
effect was completely blocked by inhibition of the FGF
receptor. Furthermore, inhibition of the FGF receptor by
itself significantly increased PTH levels, indicating that
FGF23 has a suppressive tonus on the parathyroid gland’s
PTH secretion. In acute hypocalcemia, there was no effect
of either recombinant FGF23 or FGF receptor inhibition on
the physiological response to the low ionized calcium
levels. In conclusion, FGF23 has an inhibitory tonus on
PTH secretion in normocalcemia and signals through the
FGF receptor. In acute hypocalcemia, when increased PTH
secretion is needed to restore the calcium homeostasis, this
inhibitory effect of FGF23 is abolished.
Keywords PTH  FGF23  FGFR  PD173074 
Hypocalcemia
Introduction
The primary role of parathyroid hormone (PTH) is to
prevent and reverse acute hypocalcemia by mobilizing
calcium from bone, stimulating renal Ca2? reabsorption,
and by promoting the production of the active vitamin D
metabolite calcitriol [1]. Extracellular Ca2? is the main
determinant of the secretion of PTH from the parathyroid
glands. The parathyroid glands express abundant calcium-
sensing receptor (CaSR) mRNA and protein [2]. Small
changes in extracellular Ca2? trigger CaSR-mediated
intracellular Ca2? signaling and PTH secretion [3].
The Ca2?/PTH relationship is described by a steep sig-
moidal curve. A small decline in Ca2? below normal will
result in a dramatic increase in the PTH secretion. The
maximal secretory rate, the upper part of the curve, is
achieved after just a slight degree of hypocalcemia. Induc-
tion of even mild hypercalcemia will, in contrast, result in a
modest decline of PTH secretion to its minimal level [1].
Several factors are involved in the complexity of the
Ca2?/PTH relationship such as intraglandular degradation of
PTH, recruitment of parathyroid cells in an active state,
autocrine/paracrine factors, hysteresis, rate-dependent con-
trol of the PTH response to reduction of Ca2?, and several
intraglandular factors. The detailed mechanism behind the
complexity of the Ca2? regulated PTH secretion is still not
well understood [4, 5]. The newly described crystal structure
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of CaSR extracellular domain brought important and fasci-
nating new information on the mechanisms by which Ca2?
and other ions control the parathyroid function [6, 7]. Crystal
structures of the resting and active conformation reveal
multiple binding sites for Ca2? and PO4
3- ions. While Ca2?
stabilizes the active state, PO4
3- ions reinforce the inactive
conformation of CaSR [7]. This finding further emphasizes
that calcium and phosphate homeostases are interrelated at
the level of parathyroids as previously indicated by our group
and others showing direct regulatory effect of phosphate on
PTH secretion [8–10].
Fibroblast growth factor 23 (FGF23) activates the FGF
receptor (FGFR) in the presence of the obligate co-receptor
aKlotho and the parathyroid gland expresses both FGFRs
and aKlotho [11–13]. FGF23 has been proposed to have
several effects on the parathyroid glands such as decreasing
PTH gene expression and secretion, increasing the parathy-
roid glands expressions of CaSR, vitamin D receptor (VDR),
and aKlotho, altogether contributing to the suppression of
PTH [12, 14]. Recently, it was shown that FGF23 via acti-
vation of the aKlotho/FGF receptor signaling is positively
associated with parathyroid cell proliferation [15].
Clinical observations of either high or low FGF23 levels
have shown very varied plasma PTH levels [16]. As
alteration in FGF23 levels also induces changes in the
levels of calcitriol, Ca2?, and phosphate, it can be difficult
to unravel the direct effect of FGF23 on PTH levels.
Experimental studies on the direct effect of FGF23 on the
parathyroid gland have shown an inhibitory effect on PTH
mRNA and hormone secretion [12, 14]. However, the
physiological function of the inhibitory effect of FGF23 on
the parathyroid gland’s PTH gene expression and PTH
secretion is not well understood. The parathyroid gland
loses rapidly its responsiveness to extracellular calcium
ex vivo and there has currently not been established a
functional parathyroid cell line [17, 18]. Therefore, the aim
of the present investigation was to study the impact of
FGF23 on the Ca2?/PTH relationship in vivo under con-
ditions of normocalcemia and hypocalcemia. The present
study demonstrates for the first time that FGF23 has an
inhibitory tonus on PTH secretion when plasma Ca2? is
within normal range. At low plasma Ca2?, when increased
PTH secretion is needed to restore Ca2? levels, this inhi-
bitory effect of FGF23 on PTH secretion is abolished.
Materials and Methods
Animals
Adult male Wistar rats (200 g) were used for the study
(Charles Rivers Laboratories, GmbH, Germany). They
were housed in an accredited facility with a 12-h light/dark
circle. The rats had free access to water and standard diet
containing 0.7% calcium, 0.5% phosphorus, and 600 IU
vitamin D per kg (Altromin, Lage, Germany).
Study Approval
The experiments were conducted in accordance to the
national guidelines for care and use of laboratory animals.
The experimental protocols were approved by the Danish
Animal Experiments Inspectorate (license 2012-DY-2934-
00023).
Experimental Protocols
The rats were allocated to one of the following models:
(1) Treatment with recombinant FGF23 (rFGF23) in
normocalcemic condition (n = 4).
(2) Treatment with FGF Receptor inhibitor (FGFRi) and
rFGF23 in normocalcemic condition (n = 9).
(3) Treatment with a combination of rFGF23 or vehicle
and induction of acute hypocalcemia (n = 12).
(4) Treatment with a combination of FGFRi or vehicle
and induction of acute hypocalcemia (n = 12).
The rats were anesthetized with pentobarbital (50 lg/
kg) intraperitoneally. A catheter was placed in the femoral
vein for intravenous infusion and a catheter was placed in
the femoral artery for blood sampling. Blood was drawn at
baseline and at times 0, 5, 10 min, and subsequently every
10 min. Same volume of isotonic saline was administered
after blood sampling to restore blood volume.
We used full-length human rFGF23 (R&D Systems,
Minneapolis, MN) dissolved in sterile phosphate-buffered
saline according to manufacturer’s recommendation and
diluted in isotonic saline to a volume of 100 ll. The
rFGF23 was given as an intravenous bolus injection.
Vehicle consisted of 100 ll isotonic saline. The FGF
receptor inhibitor PD173074 (L&C Laboratory, Woburn,
MA) 40 mg was dissolved in 200 ll 96% ethanol and
administered by oral gavage. Vehicle consisted of 200 ll
96% ethanol. In model 2, increasing doses of rFGF23 were
administered to groups of rats, 0.1 lg rFGF23 (n = 5),
1 lg rFGF23 (n = 2), and 10 lg rFGF23 (n = 2). Acute
hypocalcemia was induced by a continuous intravenous
infusion of 40 mM EGTA (ethylene-bis(oxyethyleneni-
trilo)tetraacetic acid; Sigma, USA) at a rate of 3.0 ml/h
[19].
Biochemistry
Plasma Ca2? was measured by a calcium selective elec-
trode (ABL505, Radiometer, Copenhagen, Denmark).
Plasma FGF23 was measured using the intact FGF23
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enzyme-linked immunosorbent assay (Kainos Laboratory,
Tokyo, Japan) measuring both rat and human FGF23. The
intra- and inter-assay coefficients of variation in our labo-
ratory were 2.5 and 5%, respectively [13]. PTH was mea-
sured by an ELISA method (Immutopics, San Clemente,
CA). The inter-assay and intra-assay coefficients of varia-
tion of this PTH ELISA were, respectively, 9 and 4% in our
laboratory [5].
Statistical Analyses
Normal distribution of data was assessed in GraphPad
Prism 7. Data are expressed as mean ± SEM. Statistical
significance was tested using paired or unpaired two-sided
t test calculated in Excel and GraphPad Prism 7. Signifi-
cance level was set at p B 0.05.
Results
Effect of FGF23 and FGF Receptor Inhibition
on the Plasma Levels of PTH in Normocalcemia
To study the effect of FGF23 on PTH levels in plasma, we
administered rFGF23 by an intravenous bolus injection in
normal rats. The rats were given 0.1 lg rFGF23 resulting
in a significant increase in plasma levels of intact FGF23
from 83 ± 21 to 907 ± 101 pg/ml (p\ 0.01). The
rFGF23 was rapidly cleared from the circulation and
FGF23 levels became close to baseline levels after
20–30 min (Fig. 1a). This is in accordance with our pre-
vious finding of a short half-life of FGF23 [20]. The
rFGF23 caused a significant decrease in the plasma levels
of PTH already at 10 min (p\ 0.01) and subsequent lower
levels of PTH (Fig. 1b).
In order to examine whether FGF23 was signaling
through the FGF receptor, we combined administration of
FGFRi PD173074 and rFGF23. FGFRi resulted in a sig-
nificant decrease in plasma iFGF23 levels from 116 ± 37
to 21 ± 11 pg/ml (p\ 0.05) and in a simultaneous
increase in plasma levels of PTH from 38 ± 10 to
270 ± 50 pg/ml after 4 h (p\ 0.05, Fig. 1c), indicating
that FGF23 signaling via the FGFR has an inhibitory tonus
on PTH secretion. When 0.1 lg of rFGF23 was given after
prior FGFRi, it had no suppressive effect on the plasma
levels of PTH (Fig. 1c). Increasing doses, 1 and 10 lg, of
rFGF23 resulted in very high plasma levels of FGF23
around 12,000 and 120,000 pg/ml, respectively. However,
these high FGF23 levels did not suppress PTH levels when
the FGFR was inhibited (data not shown).
Effect of FGF23 on the Plasma Levels of PTH
in During Hypocalcemia
To study the effect of FGF23 on PTH secretion in the
setting of hypocalcemia, the parathyroid glands’ PTH
secretion was stimulated by induction of acute hypocal-
cemia using a continuous intravenous EGTA infusion. The
EGTA infusion resulted in a significant drop in plasma
Ca2? levels (Fig. 2a) and after 5 min of infusion the
maximum PTH secretory response was obtained (Fig. 2b).
After 30 min of EGTA infusion and during maximal PTH
secretion, an intravenous bolus of 1 lg of rFGF23 or
vehicle was given. The rFGF23 injection significantly
increased plasma levels of FGF23 to 1774 ± 400 versus
262 ± 51 pg/ml in the vehicle group (p\ 0.01). In spite of
these high FGF23 levels, rFGF23 had no suppressive effect
on PTH levels during hypocalcemia (Fig. 2b).
Effect of FGFRi on the Plasma Levels of PTH
in During Hypocalcemia
In order to study the effect of FGFRi on PTH secretion in
the setting of hypocalcemia, we administered the FGFRi
PD173074 or vehicle prior to induction of acute hypocal-
cemia by EGTA infusion. The FGFRi treatment alone had
no effect on plasma levels of Ca2? (Fig. 3a). The EGTA
infusion rapidly decreased the plasma levels of Ca2? in rats
treated with vehicle and in rats treated with FGFRi with no
difference between the two groups (Fig. 3a). Again FGFRi
resulted in a significant increase in plasma PTH levels from
85 ± 13 to 182 ± 10 pg/ml (p\ 0.01). Stable PTH levels
were found in the vehicle-treated rats, 104 ± 22 versus
124 ± 25 pg/ml (Fig. 3b). The parathyroid glands
responded immediately to the decrease in plasma Ca2?
with a large and significant increase in plasma PTH levels,
obtaining maximum levels already after 5 min of EGTA
infusion. In the vehicle-treated rats PTH increased from
124 ± 25 to 347 ± 61 pg/ml (p\ 0.01) and in the FGFRi-
treated rats PTH increased from 184 ± 10 to 316 ± 22 pg/
ml (p\ 0.01). There was no difference in the maximum
PTH secretory response to hypocalcemia in the two groups
(Fig. 3b). The plasma Ca2? concentration continued to
decrease at a similar rate during the EGTA infusion in both
groups and reached low levels of 0.97 ± 0.03 mM (vehicle
rats) and 0.98 ± 0.03 mM (FGFRi rats) after 60 min. The
maximal plateau of PTH secretion obtained after the
transient maximum PTH secretory response was the same
in the two groups (Fig. 3b).
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Discussion
We used an in vivo model to examine the regulatory
function of FGF23 on the plasma levels of PTH and
demonstrated that FGF23 has an inhibitory tonus on PTH
secretion, but only when the plasma concentration of Ca2?
is within normal range. At low plasma Ca2? levels, when
increased PTH secretion is needed in order to restore
normal Ca2? levels, this inhibitory effect of FGF23 is
abolished. Furthermore, we clearly demonstrated that the
suppressive effect of FGF23 in normocalcemia is mediated
through the FGF receptor.
A suppressive effect of FGF23 on PTH production and
secretion has previously been shown by Ben-Dov et al.
They demonstrated a rapid suppressive effect of intra-
venous FGF23 on plasma PTH levels. This was mediated
by phosphorylation of ERK1/2 as an indication of
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activation of the MAPK pathway [12]. Furthermore, they
injected rats with FGF23 daily for 5 days and confirmed
the decrease in plasma PTH levels by a decrease in PTH
mRNA. Their studies were done in normocalcemia [12]. A
suppressive effect of daily FGF23 injections on PTH levels
in normal rats and activation of the MAPK/ERK1/2 sig-
naling pathway has also been shown by Canalejo et al.
[21]. Activation of the aKlotho-FGFR complex by FGF23
has been shown to conduct downstream signaling through
the MAPK/ERK1/2 pathway and this pathway is activated
by FGF23 in the kidney [22]. Krajisnik et al. found ex vivo
in bovine parathyroid glands a dose-dependent increase in
Egr-1 mRNA, an early response gene of the MAPK/ERK1/
2 signaling pathway, after co-incubation with two doses of
recombinant FGF23 for 1 h and later a decrease in PTH
mRNA and PTH concentration after 12 and 24 h, respec-
tively [14]. Even though they found an early activation of
the MAPK/ERK1/2 pathway, the effect of FGF23 on PTH
levels was very late as compared to our in vivo results and
to the study of Ben-Dov et al. The new findings in the
present investigation provide a better understanding on
how and when this inhibitory effect of FGF23 on PTH
secretion is mediated and stress the impact of normocal-
cemia in physiological and pathophysiological conditions
for the regulation to prevail. We confirm that the effect of
FGF23 in normocalcemia is mediated via the FGF receptor
in the parathyroid gland as shown in the present investi-
gation by the use of a pharmacological FGF receptor
inhibitor.
FGF23 is known to activate FGFR1 isoform IIIc,
FGFR3 isoform IIIc, and FGFR4 [11]. Binding of the FGF
ligand causes a dimerization of the FGF receptor and
induces autophosphorylation of the intracellular domain
and activation of downstream signaling of MAPK/ERK1/2,
PI3 K/AKT, STAT, and PLCc pathways [23]. We and
others have previously shown that the parathyroid gland
expresses high levels of FGFR1, FGFR2 and to a less
extent FGFR3 and FGFR4 [13, 15]. We used a pan FGFR
inhibitor in the present study and are therefore not able to
identify which subtype of the FGF receptors that FGF23
activates in the parathyroid gland. Furthermore, PD173074
also inhibits the tyrosine kinase activity of vascular
endothelial growth factor (VEGF) receptor. As such, an
effect of this compound on other receptors than FGFR in
the parathyroids cannot be excluded.
Upon stimulation of CaSR a number of intracellular
signal transduction pathways are activated, among them are
phosphoinositide-specific phospholipase C and MAPK/
ERK1/2. Characteristic for PTH secretion is that it is
increased at low intracellular Ca2? levels and suppressed
by an increase in intracellular Ca2? level, where the latter
is caused by activation of CaSR [3]. Activation of the
FGFRs leads to phosphorylation of PLCc, which hydrol-
yses phosphatidylinositol 4,5 biphosphate to produce
inositol triphosphate (IP3). IP3 increases intracellular Ca
2?
concentration [23]. FGF23 has been demonstrated to
increase the intracellular Ca2? level in cardiomyocytes
[24]. Potentially, this mechanism might explain the rapid
inhibitory effect of FGF23 on PTH secretion. Further
research is however needed to clarify the signal transduc-
tion of FGF23 on intracellular calcium in the parathyroid
cell.
Even though most studies confirm the obligatory func-
tion of aKlotho in converting the FGFR to be specific for
FGF23 signaling, a recent study questions the necessary
co-receptor function of aKlotho in the parathyroid gland,
as a specific deletion of the aKlotho gene in the parathyroid
gland did not abolish the effect of FGF23 [25]. In wildtype
mice, FGF23 activated the MAPK/ERK1/2 pathway in the
parathyroid glands and suppressed PTH levels. However,
in genetically manipulated mice with a specific aKlotho
gene deletion in the parathyroid glands, FGF23 activated
the calcineurin pathway and suppressed PTH levels [25].
20 40 60
0.7
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5
C
a2
+
m
M
vehicle
FGFRi
FGFRi
vehicle
(5h)
EGTA infusion
Time (min)
20 40 60
0
100
200
300
400
500
PT
H
pg
/m
l
vehicle
FGFRi
**
Time (min)
FGFRi
vehicle
(5h)
EGTA infusion
a b
Fig. 3 FGF receptor inhibition has no effect on PTH secretion in
hypocalcemia. a FGFRi or vehicle was administered prior to
induction of acute hypocalcemia by a continuous EGTA infusion
that rapidly decreased plasma Ca2? (p\ 0.001). b FGFRi resulted
again in a significant increase in PTH levels (p\ 0.01). The rapid
increase in PTH levels in response to acute hypocalcemia was
however similar between the two groups. Data are expressed as
mean ± SEM. **p\ 0.01 n = 6 in each group
M. L. Mace et al.: Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels… 89
123
Kawakami et al. used genetic-manipulated models,
specific deletion of FGFRs and aKlotho in the parathyroid
glands of mice, and found in wildtype mice an acute sup-
pressive effect of FGF23 on PTH secretion after 1 h in
accordance to our findings [15]. In the FGFR1-3 and
aKlotho knocked-out models, the effect of FGF23 on PTH
levels was abolished further supporting our findings of
FGF23 signaling through the FGF receptor in the
parathyroid gland.
Chronic kidney disease causes disturbances in the min-
eral balance and concomitant high levels of plasma FGF23
and PTH. In a previous investigation, we administered the
FGF receptor inhibitor, PD173074, to uremic normocal-
cemic rats and found a large increase in plasma PTH
indicating that the suppressive tonus of FGF23 on the
parathyroid gland is still present in uremia, when plasma
Ca2? is within normal range [26]. Galitzer et al. also found
a suppressive effect of FGF23 on the parathyroid glands in
uremic rats after 2 weeks of uremia induced by adenine
diet [27]. These uremic rats had the same expression of
aKlotho in the parathyroid gland as normal rats, but
reduced FGFR1 expression. After 6 weeks of uremia, both
aKlotho and FGFR1 expressions were reduced and they
found no effect of FGF23 on the parathyroid gland [27].
However, other studies suggest that the parathyroid glands
in uremia might be resistant to the high plasma levels of
FGF23 as shown both in vivo and in vitro by Canalejo et al
[21]. It is currently believed that parathyroid resistance to
FGF23 could be due to downregulation of aKlotho in the
parathyroid gland [16, 27, 28]. However, we did not find a
downregulation of parathyroid aKlotho expression in a
previous study on uremic 5/6-nephrectomized rats and
other researchers have reported a varied aKlotho expres-
sion within a uremic parathyroid gland [13, 29].
The present investigation is dealing with the acute
minute-to-minute regulation of the Ca2?/PTH relationship.
Hypocalcemia is a common complication to kidney failure
and therefore on the basis of our present results we propose
an additional mechanism behind the resistance of the
parathyroid gland to FGF23 in uremia, as the low plasma
Ca2? levels overrule the inhibitory effect of FGF23. Fur-
ther studies are needed to examine the resistance in chronic
hypocalcemia, another frequent finding in chronic uremia.
Collectively all studies may illustrate the gradual change
from normal physiology to a severe pathophysiology with
development of a more and more dysplastic autonomous
secreting parathyroid gland with downregulation of CaSR,
VDR, aKlotho, and FGFR1.
Our results in vivo are in contrast to an ex vivo study on
rat parathyroid glands, where FGF23 still had a suppressive
effect on PTH secretion and PTH mRNA when the
parathyroid cells were incubated at low calcium for 6 h
[21]. These discrepant results may be due to in vivo versus
in vitro models. Abolishment of an inhibitory effect during
hypocalcemia is known from other endocrine regulatory
mechanisms as it has been demonstrated for calcitriol’s
regulation of PTH transcription [30]. Thus, in chronic
hypocalcemia there is a marked increase in calcitriol,
which has no suppressive effect on PTH levels; they are
significantly increased as well [30]. The mechanism behind
these findings has been proposed to be due to the binding of
calreticulin to VDR-RXRb to VDRE of the PTH promoter
[31]. The levels of Ca2? have been reported also to control
FGF23 levels [32, 33]. Therefore, the complex interplay
between the calcium and phosphate regulating hormones
may also be influenced by the extracellular Ca2? concen-
tration and thus facilitate the ability of the organism to
maintain the crucial Ca2? homeostasis for normal cellular
and organ function [20, 34].
All FGF receptors have a cluster of acidic amino acids
in their extracellular region. It has been demonstrated that
FGFR1 binds Ca2?, although low Ca2? in the media did
not alter the binding of the ligand FGF2 in a cell line [35].
It is however not known if this region affects the interac-
tion in ligand-receptor binding for other FGFRs and
ligands. It has been proposed that the binding of a divalent
cation will result in a loop configuration in this region that
could alter the 3D configuration of the receptor and facil-
itate ligand binding. Thus a study on cloned FGF receptors
found a weaker ligand-receptor binding when rat parathy-
roid cells were incubated at low calcium concentration
[36].
FGF23’s suppressive effect on PTH may be part of a
classical endocrine feedback loop, where PTH stimulates
FGF23 expression via the PTH receptor 1 and possibly by
activation of Nurr1 transcription [37–40]. Both hormones
have phosphaturic effects, yet they impose a counter reg-
ulation on calcitriol with a stimulatory effect of PTH and
an inhibitory effect of FGF23. Furthermore, the regulatory
loop between FGF23 and PTH seems to be complex and
also depending on the extracellular Ca2? concentration, as
shown in the present data. Our study is dealing with the
acute effect of FGF23 on PTH secretion, and it has to be
emphasized that most clinical scenarios of high FGF23 are
chronic and the interpretation from the present acute
experiments cannot directly be transferred to image the
situation in long-term increase of FGF23 levels.
In conclusion, FGF23 has an inhibitory tonus on PTH
secretion when extracellular Ca2? calcium is within normal
range. This regulation is part of a complex endocrine
system consisting of FGF23, PTH, and calcitriol, which
maintains Ca2? and phosphate homeostasis. In hypocal-
cemia, when increased PTH secretion is needed to restore
the calcium homeostasis, this inhibitory effect of FGF23 is
abolished.
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